Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
AssigneeSynlogic Operating Company, Inc.
InventorsDean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
Life of this patent
Estimating the term…
Abstract
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Claims18
A genetically engineered non-pathogenic bacterium comprising a non-native gene encoding interleukin (IL)-22, wherein the gene is operably linked to a promoter, and a non-native gene cassette for producing butyrate, wherein the gene cassette is operably linked to a promoter, wherein at least one promoter comprises any one of SEQ ID NOs:
- 142-157.
A genetically engineered non-pathogenic bacterium comprising a non-native gene encoding interleukin (IL)-22, and a non-native gene cassette for producing butyrate, wherein the gene and the gene cassette are operably linked to the same copy of a promoter comprising any one of SEQ ID NOs:
- 142-157.
Dependencies are inferred from the claim text.